Navigation Links
Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer

ASCO Oral Presentation Reports Significantly More Patients Treated with Taxotere(R)-Based Chemotherapy Regimen Survived at Least Three Years

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Taxotere(R) (docetaxel) Injection Concentrate-based chemotherapy (Taxotere plus prednisone) maintained long-term efficacy as a treatment for advanced (metastatic) hormone-resistant prostate cancer patients, according to the three-year updated results of the landmark TAX 327 study. Results of the international multi-center phase III trial were reported in an oral presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

The TAX 327 data show that among patients with metastatic hormone- resistant prostate cancer, significantly more of those treated with Taxotere(R) 75mg/m2 combined with prednisone 5 mg once every three weeks survived at least three years, than those treated with anti-cancer antibiotic mitoxantrone combined with prednisone. Patients treated with the Taxotere(R) regimen lived a median of three months longer (19.3 months versus 16.3 months, p=0.006) and had a 21% lower risk of dying (HR=17.6-21.3). These results are consistent with results published in 2004 in the New England Journal of Medicine and document the maintenance of the survival benefit previously reported in patients treated with the Taxotere-based therapy.

"The results confirm docetaxel's survival benefit in patients with metastatic hormone resistant prostate cancer," said study author Dominik R. Berthold, Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada. "Prolonged survival is extremely important for these patients and docetaxel is the only chemotherapeutic agent to demonstrate a survival benefit in this setting."

Original TAX 327 Analysis Showed Improved Survival

The TAX 327 study was initiated in 2000 to evaluate long-term survival among men with metastatic h
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
3. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 /PRNewswire/ ... the prostate cancer treatment continuum was highlighted prominently ... the American Urological Association (AUA), in San Diego.  ... invasive high intensity focused ultrasound (HIFU) technology, the ... localize disease, and for urologists to consider minimally ...
(Date:5/23/2013)... 2013  Texas, premier physician associations today announced the ... tools they need to provide demonstrably better and more ... marketplace. "I am confident the Physician Services ... Stephen L. Brotherton , MD, president ... doctors are determined to make health care ...
(Date:5/23/2013)... May 23, 2013   Direct to implant, ... is an appropriate option for many women with ... reduce their breast cancer risk, or with breast ... process and a second surgery to insert permanent ... same surgery as mastectomy can be a medically ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3
... Inc. ("Senesco" or the "Company") (Amex: SNT ... Inc. (The Woodlands, TX) ("VGXI") to,supply the plasmid ... Factor 5A gene and siRNA against Factor 5A., ... vivo results,using its combination siRNA and plasmid against ...
... Continuing Education Newsletter Series for Healthcare ... ... is a serious condition that causes disease with a wide spectrum ... can occur in up to 20% of patients who develop an ...
Cached Medicine Technology:Senesco Chooses VGXI to Produce Factor 5A Plasmid 2Senesco Chooses VGXI to Produce Factor 5A Plasmid 3Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease 2
(Date:5/24/2013)... 2013 Amirsys today announces the release ... for instructors and students. Instructors can use the new ... learning plan templates, targeted reading assignments, and customized instructions. ... assessment questions, 5,000 searchable anatomy glossary terms, and easier ... 2.0 is the first gross anatomy resource to ...
(Date:5/24/2013)... myofibromatosis (IM)a disorder characterized by multiple tumors involving the ... according to researchers from the Icahn School of Medicine ... American Journal of Human Genetics , may lead to ... the only current treatment option is repeated surgical removal ... that develops in infancy or even in utero and ...
(Date:5/24/2013)... May 24, 2013 Mike Stoler believes ... most successful business people in New York. That’s ... airs weekly on CUNY TV. And that’s why ... and Allergy Associates, LLP (ENTA)—the largest single specialty practice ... nose, throat, allergy and audiology specialists and sub-specialists service ...
(Date:5/24/2013)... 6Webs.com has educated thousands of buyers on what ... monitoring provider. The easy to read reviews and ... prefer for unbiased and impartial home security reviews. 6Webs.com ... wireless home security system providers in the nation. The ... of key factors including reliability, technology and equipment. ...
(Date:5/24/2013)... May 24, 2013 The Dictation Source ... base of clients. As a result of its National ... presence in 20 states around the nation. , Since ... transcription services to the healthcare industry . Dictation Source ... use their years of clinical work experience to provide ...
Breaking Medicine News(10 mins):Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:2013 Best Wireless Security System Providers Reported by 6Webs.com 2Health News:The Dictation Source Signs Two National Hospital Chains 2Health News:The Dictation Source Signs Two National Hospital Chains 3
... to Visit Washington, D.C., and Meet with Elected Officials, ... will travel to Washington, D.C., this April 1 to ... of the,Americans with Disabilities Act, support for epilepsy public ... Serwik, 7, is one of 50 young people ...
... Visit Washington, D.C., and,Meet with Elected Officials, ... Nicklaus Schliesmann of Holmen will travel to Washington,D.C., ... and gain their,support for restoration of the Americans ... and more research toward a cure for,epilepsy., ...
... D.C., and Meet with Elected Officials, WASHINGTON, March ... travel to Washington, D.C., this April 1 to meet ... the,Americans with Disabilities Act, support for epilepsy public health,programs ... Smith, 15, is one of 50 young people with ...
... Corporation,(NYSE: STE ) today announced that its ... to $300 million in shares of STERIS common ... as of,February 29, 2008. This share repurchase authorization ... remaining. Through March,13, 2008, the Company has repurchased ...
... in Handling Credit ... Fraud, ... he has reached a settlement with TransUnion over his,lawsuit against the credit ... is the first of six credit reporting companies and banks,which Drew has ...
... LINTHICUM, Md., March 13 Dialysis Corporation,of America ... that it will begin,hosting conference calls in conjunction ... The conference call will he held,Friday morning, March ... interested may dial in at 800-750-4984 using pass-code ...
Cached Medicine News:Health News:Delaware Youth Named National Epilepsy Spokesperson 2Health News:Wisconsin Youths Named National Epilepsy Spokespersons 2Health News:South Carolina Youth Named National Epilepsy Spokesperson 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 3Health News:Leukemia Survivor Reaches Landmark Settlement With TransUnion in ID Theft Case 2Health News:Dialysis Corporation of America Earnings Call Reminder 2
... dryer is an electrophoresis gel vacuum dryer that ... dries these gels onto cellophane or filter paper ... elements which heat gels from above. The drying ... V unit includes power cord, porous gel support, ...
... constant voltage power supply, the 105 is very ... range switch control the output, which is variable ... One, two-position switch toggles the bright LED display ... 105 is equipped with an over current detector ...
... simple techniques such as submarine electrophoresis and ... IEF, the Series 90 Programmable Power Supplies ... 90 Programmable Power Supplies are available in ... 6000V., All models operate in constant voltage, ...
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Medicine Products: